Facile fabrication of a novel hybrid nanoparticles by self-assembling based on pectin-doxorubicin conjugates for hepatocellular carcinoma therapy

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. Ca Cancer J Clin. 2016;66:115–132.
   PubMed Web of Science ®Google Scholar
• Zamani P, Riahi MM, Momtaziborojeni AA, et al. Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma. Artifi Cell Nanomed Biotechnol. 2017;1:1–13.
   Google Scholar
• Huang X, Zhang W, Guan G, et al. Design and functionalization of the nir-responsive photothermal semiconductor nanomaterials for cancer theranostics. Acc Chem Res. 2017;50:2529–2538.
   PubMed Web of Science ®Google Scholar
• Li Y, Lin J, Liu G, et al. Dual-acting, function-responsive, and high drug payload nanospheres for combining simplicity and efficacy in both self-targeted multi-drug co-delivery and synergistic anticancer effect. Int J Pharm. 2016;512:194–203.
   PubMedGoogle Scholar
• Zhu W, Li Y, Liu L, et al. Supramolecular hydrogels as a universal scaffold for stepwise delivering Dox and Dox/cisplatin loaded block copolymer micelles. Int J Pharm. 2012;437:11–19.
   PubMed Web of Science ®Google Scholar
• Pan JX, Chen G, Li JJ, et al. Isocorydine suppresses doxorubicin-induced epithelial-mesenchymal transition via inhibition of ERK signaling pathways in hepatocellular carcinoma. Am J Cancer Res. 2018;8:154–164.
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16:3267–3285.
   PubMed Web of Science ®Google Scholar
• Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev. 1995;16:285–294.
   Web of Science ®Google Scholar
• Ak G, Yɪlmaz H, Sanlɪer SH. Preparation of magnetically responsive albumin nanospheres and in vitro drug release studies. Artifi Cell Nanomed Biotechnol. 2014;42:18–26.
   PubMed Web of Science ®Google Scholar
• Li M, Bu W, Ren J, et al. Enhanced synergism of thermo-chemotherapy for liver cancer with magnetothermally responsive nanocarriers. Theranostics. 2018;8:693–709.
   PubMed Web of Science ®Google Scholar
• Hu R, Zheng H, Cao J, et al. Synthesis and in vitro characterization of carboxymethyl chitosan-cba-doxorubicin conjugate nanoparticles as pH-sensitive drug delivery systems. J Biomed Nanotechnol. 2017;13:1097–1105.
   PubMed Web of Science ®Google Scholar
• Hu R, Zheng H, Cao J, et al. Self-assembled hyaluronic acid nanoparticles for pH-sensitive release of doxorubicin: synthesis and in vitro characterization. J Biomed Nanotechnol. 2017;13:1058–1068.
   PubMed Web of Science ®Google Scholar
• Li Y, Yang DD, Zhang Y, et al. Novel DSPE-PEG-cholic acid-modified liposomes with hepatic targeting properties improve the anti-tumor efficacy of oral doxorubicin hydrochloride for liver tumor-bearing mice. J Biomed Nanotechnol. 2017;13:727–736.
   Web of Science ®Google Scholar
• Hu DR, Chen LJ, Qu Y, et al. Oxygen-generating hybrid polymeric nanoparticles with encapsulated doxorubicin and chlorin e6 for trimodal imaging-guided combined chemo-photodynamic therapy. Theranostics. 2018;8:1558–1574.
   PubMed Web of Science ®Google Scholar
• Qu Y, Niu T, Liu ZG, et al. Recent progress of doxorubicin nanomedicine in hematologic malignancies. Nanosci Nanotechnol Lett. 2017;9:1861–1874.
   Google Scholar
• Yao C, Tian J, Wang H, et al. Loading-free supramolecular organic framework drug delivery systems (sof-DDSs) for doxorubicin: normal plasm and multidrug resistant cancer cell-adaptive delivery and release. Chinese Chem Lett. 2017;28:893–899.
   Web of Science ®Google Scholar
• Ji F, Li J, Qin Z, et al. Engineering pectin-based hollow nanocapsules for delivery of anticancer drug. Carbohydr Polym. 2017;177:86–96.
   PubMed Web of Science ®Google Scholar
• Zheng G, Zhao R, Xu A, et al. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy. Eur J Pharm Sci. 2018;111:492–502.
   PubMed Web of Science ®Google Scholar
• Zhao R, Li T, Zheng G, et al. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. Biomaterials. 2017;143:1–16.
   PubMed Web of Science ®Google Scholar
• Yu CY, Yang S, Li ZP, et al. The in-situ one-step synthesis of a PDC macromolecular pro-drug and the fabrication of a novel core-shell micell. Curr Pharm Des. 2016;22:506–513.
   PubMed Web of Science ®Google Scholar
• Li ZP, Jiang MC, Chen B, et al. Fabrication and characterization of a novel self-assembling micelle based on chitosan cross-linked pectin–doxorubicin conjugates macromolecular pro-drug for targeted cancer therapy. Rsc Adv. 2018;8:12004–12016.
   PubMed Web of Science ®Google Scholar
• Nafee N, Forier K, Braeckmans K, et al. Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls. Eur J Pharm Biopharm. 2018;124:125–137.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Peng Z, Seven ES, et al. Crossing the blood-brain barrier with nanoparticles. J Control Release. 2018;270:290–303.
   PubMed Web of Science ®Google Scholar
• Zhang YN, Poon W, Tavares AJ, et al. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332–348.
   PubMed Web of Science ®Google Scholar
• Wang H, Thorling CA, Liang X, et al. Diagnostic imaging and therapeutic application of nanoparticles targeting the liver. J Mater Chem B. 2015;3:939–958.
   PubMed Web of Science ®Google Scholar
• Gershwin ME, Vierling JM, Manns MP. Liver immunology: principles and practice. 2nd ed. Germany: Springer; 2013.
   Google Scholar
• Takakura Y, Mahato RI, Hashida M. Extravasation of macromolecules. Adv Drug Deliv Rev. 1998;34:93–108.
   PubMed Web of Science ®Google Scholar
• Gaumet M, Vargas A, Gurny R, et al. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69:1–9.
   PubMed Web of Science ®Google Scholar
• Xu L, Xu S, Wang H, et al. Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: the Combination of Polymeric Prodrug Design, Nanoparticle Encapsulation, and Cancer Cell-Specific Drug Targeting. Acs Appl Mater Interfaces. 2018;10:3229–3240.
   PubMed Web of Science ®Google Scholar
• Yu CY, Cao H, Zhang XC, et al. Hybrid nanospheres and vesicles based on pectin as drug carriers. Langmuir. 2009;25:11720–11726.
   PubMed Web of Science ®Google Scholar
• Yu CY, Wang YM, Li NM, et al. In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy. Mol Pharmaceutics. 2014;11:638–644.
   PubMed Web of Science ®Google Scholar
• Lessa EF, Gularte MS, Garcia ES, et al. Orange waste: a valuable carbohydrate source for the development of beads with enhanced adsorption properties for cationic dyes. Carbohydr Polym. 2017;157:660–668.
   PubMed Web of Science ®Google Scholar
• Chambin O, Dupuis G, Champion D, et al. Colon-specific drug delivery: influence of solution reticulation properties upon pectin beads performance. Int J Pharm. 2006;321:86–93.
   PubMed Web of Science ®Google Scholar
• Kiziltepe T, Ashley JD, Stefanick JF, et al. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacyin vivo. Blood Cancer J. 2012;2:e64.
   PubMed Web of Science ®Google Scholar
• Tran TH, Chi TN, Gonzalez-Fajardo L, et al. Long circulating self-assembled nanoparticles from cholesterol-containing brush-like block copolymers for improved drug delivery to tumors. Biomacromolecules. 2014;15:4363–4375.
   PubMed Web of Science ®Google Scholar